Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
International Journal of Molecular Sciences · 28.05.2023 · 24 (11) · 9388
DOI: 10.3390/ijms24119388 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.05.2023. Verfasst von Patricia Richter und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Lupus Erythematosus, Systemic, Scleroderma, Systemic, Connective Tissue Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Interstitial lung disease (ILD) is a severe and frequent manifestation of connective tissue diseases (CTD). Due to its debilitating potential, it requires serious evaluation and treatment. The prevalence of ILD in systemic lupus erythematosus (SLE) is still controversial. Therefore, in order to establish the diagnosis of ILD, an overlap syndrome must be excluded. Increasing the identification of SLE-associated ILD cases should become a target. To treat this complication, various therapies are now being proposed. To date, no placebo-controlled studies were conducted. Regarding another CTD, systemic sclerosis (SSc), SSc-associated ILD is considered one of the leading causes of mortality. The incidence of ILD varies among disease subtypes, being influenced by diagnostic method, but also by disease duration. Due to the high prevalence of this complication, all SSc patients should be investigated for ILD at the time of SSc diagnosis and during the course of the disease. Fortunately, progress was made in terms of treatment. Nintedanib, a tyrosine kinases inhibitor, showed promising results. It appeared to decrease the rate of progression of ILD compared to placebo. This review aimed to provide up-to-date findings related to SLE-associated ILD and SSc-associated ILD, in order to raise awareness of their diagnosis and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
- Clinical Rehabilitation Hospital, 700661 Iasi, Romania.
- Department of Internal Medicine, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
- "Sf. Spiridon" Clinical Emergency Hospital, 700111 Iasi, Romania.
ORCID-Profile: Anca Cardoneanu, Ioana Bratoiu, Alexandra Maria Burlui, Luana Andreea Macovei
Zitieren
APA
Richter, P., Cardoneanu, A., Dima, N., Bratoiu, I., Rezus, C., Burlui, A. M., Costin, D., Macovei, L. A., & Rezus, E. (2023). Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?. International Journal of Molecular Sciences, 24(11), 9388. https://doi.org/10.3390/ijms24119388
Vancouver
Richter P, Cardoneanu A, Dima N, Bratoiu I, Rezus C, Burlui AM, et al. Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?. International Journal of Molecular Sciences. 2023;24(11):9388. doi:10.3390/ijms24119388
BibTeX
@article{Richter2023,
author = {Richter, Patricia and Cardoneanu, Anca and Dima, Nicoleta and Bratoiu, Ioana and Rezus, Ciprian and Burlui, Alexandra Maria and Costin, Damiana and Macovei, Luana Andreea and Rezus, Elena},
title = {Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {11},
pages = {9388},
doi = {10.3390/ijms24119388}
}
EUVIMED